Shinil Pharmaceutical
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Shinil Pharmaceutical makes a wide range of medicines, including tablets, capsules, syrups, ointments, creams, injectables, and patches, and supplies them to hospitals and other medical institutions.
The company also manufactures medicines on behalf of other pharmaceutical companies, a service known as contract manufacturing (CMO). In addition, it operates a consumer brand called 'Farmtree' that offers functional cosmetics and health-supplement foods developed using its pharmaceutical expertise. It is listed on KOSDAQ, South Korea's tech and small-cap stock exchange.
Summary is AI-generated and may contain errors · figures from DART filings
Beyond its own branded medicines, Shinil runs a contract manufacturing business serving other pharmaceutical companies, giving it a second revenue stream tied to the broader Korean pharma industry.
Shinil Pharmaceutical in five facts
What does Shinil Pharmaceutical do?
Shinil Pharmaceutical makes a wide range of medicines, including tablets, capsules, syrups, ointments, creams, injectables, and patches, and supplies them to hospitals and other medical institutions.
Where is Shinil Pharmaceutical listed and in which sector?
Shinil Pharmaceutical (Korean name: 신일제약) trades under KRX code 012790 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Shinil Pharmaceutical?
Its market capitalisation was US$57.5M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Shinil Pharmaceutical's latest annual revenue and operating profit?
For fiscal year 2025, Shinil Pharmaceutical reported revenue of US$60.8M, operating profit of US$5.6M and net income of US$5.7M, per its annual report on DART (data retrieved from DART on 2026-09-08). Revenue was down 9.9% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-08
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Shinil Pharmaceutical reported separate results for FY2025: revenue of US$54.3M (−9.9% year on year), operating profit of US$4.98M (−51.4% year on year) and net income of US$5.08M (−47.3% year on year).
Earnings · Mar 4 - Cash/in-kind dividend decision
Shinil Pharmaceutical declared a cash dividend of US$0.13 per share, equal to about 3% of the recent share price.
Dividend · Mar 4